2 not yet recruiting, 1 completed. 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
| Not applicable | 1 | Completed 1 |
Follow Zhifeng Zhao, PhD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Fluoxetine for Refractory Constipation With Somatic Symptom Disorder Features Fluoxetine, Placebo - Refractory Constipation, Somatic Symptom Disorder (DSM-5) | Phase 2 | Not yet recruiting | Zhifeng Zhao, PhD | 194 | 2026-09-01 | 2026-09-02 |
| Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study Zanidatamab, Oxaliplatin, Capecitabine - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Zhifeng Zhao, PhD | 46 | 2026-07-01 | 2026-07-06 |
| Fluoxetine for Refractory Constipation Fluoxetine, Polyethylene Glycol 400 0.4% - Refractory Constipation | Not applicable | Completed | Zhifeng Zhao, PhD | 316 | 2020-01-01 | 2025-06-18 |
Constipation (2) · Stomach Neoplasms (1)
Fluoxetine (2) · Capecitabine (1) · Oxaliplatin (1) · Polyethylene Glycols (1) · S 1 (combination) (1) · tegafur-gimeracil-oteracil (1) · tislelizumab (1) · zanidatamab (1)
China (2)
Jianjun Yang, Prof. (1) · Qingchuan Zhao, Prof. (1)